Identifying sources of error in self-monitoring of blood glucose.
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
C Kilo
Publications and source records attributed to C Kilo.
Glycemic control and bone age are independently associated with muscle capillary basement membrane width in diabetic children after puberty.
This study was undertaken to examine the possible relationships between muscle capillary basement membrane width (CBMW) and glycemic control, bone age, chronologic age, and duration of diabetes in young patients with insulin-dependent diabetes mellitus (IDDM) during different stages of pubertal development. We studied 49 males and 43 females (age, 7-20 yr) with IDDM for up to 16 yr for whom bone age and glycosylated hemoglobin (HbA1c) data were available at the time of right quadriceps muscle biopsy. Based on pubic hair Tanner stage, subjects were assigned to prepubertal (Tanner I), pubertal (Tanner II and III), and postpubertal (Tanner IV and V) groups. In 30 pubertal and prepubertal subjects, none of the variables studied was significantly correlated with CBMW. This is attributable in part to the small number of subjects in each group. In 62 postpubertal subjects, CBMW was correlated with age (r = .27, P = .03), bone age (r = .43, P = .0005), and postpubertal duration of diabetes (r = .38, P = .003) but not total duration of diabetes. In the postpubertal subjects, CBMW was correlated with HbA1c at the time of biopsy (r = .31, P = .01) but correlated more strongly with the mean of HbA1c values obtained during the 1- and 2-yr periods before biopsy (r = .37, P = .01, and r = .54, P = .03, respectively). An analysis of covariance revealed that the slopes for the regression of loge CBMW on HbA1c differed significantly (P = .02) among the three groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Adolescent↗
Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus.
Thirty-four adults with non-insulin-dependent diabetes mellitus were randomly assigned to receive either oral glyburide or oral glipizide in a multicenter comparative trial. Fasting blood glucose and hemoglobin A1c (HbA1c) were assessed at the beginning of the titration phase, the beginning of maintenance therapy, and the end of maintenance therapy. Maintenance therapy lasted approximately 3 months. The initial mean total dose of glyburide (5.4 mg) was significantly lower than that of glipizide (10.6 mg) (P = 0.04) and remained significantly lower at the beginning of maintenance therapy (7.8 mg versus 15.3 mg; P < 0.01) and at the end of the trial (10 mg versus 16.8 mg; P = 0.05). Although significant differences were not detected for fasting blood glucose or HbA1c, patients received higher total doses of glipizide compared with glyburide at the middle and final evaluations to maintain the fasting blood glucose between 3.9 and 10 mmol/L and HbA1c at < 9%. No serious adverse reactions were observed in any patient. These results indicate that doses of glipizide required to maintain blood glucose between 3.9 and 10 mmol/L and HbA1c at < 9% increased over time. Seventy-five percent of patients receiving glyburide were controlled with once-daily dosing compared with 29.4% of those treated with glipizide. Both glyburide and glipizide provide safe and effective treatment for patients with non-insulin-dependent diabetes mellitus, but more patients will benefit from once-daily therapy with glyburide.
Diabetes Mellitus, Type 2↗
Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus.
This study sought to compare the efficacy and safety of glyburide and glipizide in elderly patients with well-controlled non-insulin-dependent diabetes mellitus (NIDDM). One hundred forty-five patients aged > or = 65 years with NIDDM that was controlled for at least 3 months with oral sulfonylurea therapy were enrolled. After a washout phase, 139 patients were randomized to receive glyburide, 1.25 or 2.5 mg/day, or glipizide, 2.5 or 5 mg/day. During a 4- to 8-week titration phase, doses were adjusted according to prescribing guidelines. Patients who achieved glycemic control (fasting plasma glucose of < or = 8.9 mmol/L, or 160 mg/dl, on two consecutive occasions) entered a maintenance phase, for a total treatment period of 4 months. Hypoglycemia was defined as a fasting plasma glucose of < 3.3 mmol/L (60 mg/dl) or a random plasma glucose of < 2.8 mmol/L (50 mg/dl), with associated signs and symptoms. Most patients in both the glyburide and glipizide groups achieved satisfactory glycemic control; there were no significant differences between groups in fasting plasma glucose or hemoglobin A1c levels at any time. Of note, the mean dose of glyburide (8.5 mg/day) was approximately half that of glipizide (15.4 mg/day) at the end of the maintenance period (P = 0.009). Both regimens were well tolerated and were associated with a similarly low incidence of hypoglycemia. It was concluded that both glyburide and glipizide are suitable for the treatment of NIDDM in properly selected elderly patients.
Aged↗